In the future, researchers could use the MAS-3 cell line to conduct various experiments to verify whether PD-1/PD-L1 is effective in the treatment of carcinosarcoma and to identify new therapeutic schedules for patients with BC. This evidence concerns the gene CD274 and carcinosarcoma.